The University of Texas MD Anderson Cancer Center is one of the world's most respected centers devoted exclusively to cancer patient care, research, education and prevention. It is located in central Houston in the Texas Medical Center. MD Anderson provides cancer care at several locations throughout the Greater Houston Area and collaborates with health systems nationwide through MD Anderson Cancer Network®.
MD Anderson was created in 1941 as part of The University of Texas System. The institution is one of the nation's original three comprehensive cancer centers designated by the National Cancer Act of 1971 and is one of 53 National Cancer Institute-designated comprehensive cancer centers today.
U.S. News & World Report's "Best Hospitals" rankings has named MD Anderson the nation's top hospital for cancer care. The institution has been named one of the nation's top two hospitals for cancer care every year since the survey began in 1990.
Since 1944, more than 1.9 million people have turned to MD Anderson for cancer care.
MD Anderson pathologists refine a new patient's initial diagnosis by another institution up to 25% of the time.
MD Anderson's world-renowned physicians are extensively trained specialists who focus on one type of cancer and one aspect of treatment, giving them unrivaled expertise. 100% of MD Anderson's surgeons are trained in oncology compared to 30% in community hospitals.
MD Anderson provided uninsured or underinsured Texans more than $309 million in uncompensated care in FY22.
FY22 Patient Care Facts
pathology/laboratory medicine procedures
MD Anderson boasts one of the nation's most esteemed faculties. As of Feb. 1, 2023, the institution's educators include:
- 1 Nobel Laureate
- 8 National Academy of Medicine members
- 6 National Academy of Sciences members
- 6 Academy of Arts and Sciences members
- 51 American Association for the Advancement of Science fellows
- 13 Association of American Physicians members
- 29 American Society of Clinical Investigation members
In FY 2022, more than 5,086 trainees participated in MD Anderson educational programs. This included:
- 1,482 clinical residents and fellows
- 812 nursing trainees
- 375 School of Health Professions students
- 1,342 research trainees
- 1,032 student program participants
- 43 interns and fellows participated in special programs
Research at MD Anderson
At MD Anderson, important scientific knowledge gained in the laboratory is rapidly translated to clinical care.
MD Anderson is home to the world's largest cancer clinical trials program, providing patients with access to life-saving investigational drugs before they are approved by the Food and Drug Administration (FDA).
MD Anderson receives millions of dollars in grant funding from the Cancer Prevention Research Institute of Texas (CPRIT) for research, prevention, recruitment and training. MD Anderson received more than $32 million in funding from CPRIT in FY22.
MD Anderson holds nine National Cancer Institute Specialized Programs of Research Excellence (SPORE) grants in endometrial, prostate, melanoma, gastrointestinal, brain, leukemia, lung, ovarian and hepatocellular cancers.
FY22 Research Facts
spent on research
patents awarded to MD Anderson
drugs tested received FDA approval
2022 Clinical Trials Facts
patients in clinical trials
Commitment to Cancer Prevention
Cancer prevention plays a vital role in advancing MD Anderson's mission to end cancer.
In FY 2022:
- There were more than 33,815 patient visits to our Lyda Hill Cancer Prevention Center, which provides cancer screenings and risk-reduction services.
- 5,286 people received tobacco cessation services through our Tobacco Research and Treatment Program.
- MD Anderson held 382 cancer prevention education programs in the community.